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Background and Purpose—White matter lesion (WML) progression has been advocated as a surrogate marker in
intervention trials on cerebral small vessel disease. We assessed the rate of visually rated WML progression, studied
correlations between lesion progression and cognition, and estimated sample sizes for clinical trials with pure WML
progression vs combined WML progression-cognitive outcomes.
Methods—Those 394 participants of the Leukoaraiosis and Disability Study (LADIS) study with magnetic resonance
imaging scanning at baseline and 3-year follow-up were analyzed. WML progression rating relied on the modified
Rotterdam Progression Scale. The Vascular Dementia Assessment Scale global score and a composite score of specific
executive function tests assessed longitudinal change in cognition. Sample size calculations were based on the
assumption that treatment reduces WML progression by 1 grade on the Rotterdam Progression Scale.
Results—WML progression related to deterioration in cognitive functioning. This relationship was less pronounced in
subjects with early confluent and confluent lesions. Consequently, studies in which the outcome is cognitive change
resulting from treatment effects on lesion progression will need between 1809 subjects per treatment arm when using
executive tests and up to 18 853 subjects when using the Vascular Dementia Assessment Scale score. Studies having
WML progression as the sole outcome will need only 58 or 70 individuals per treatment arm.
Conclusions—WML progression is an interesting outcome for proof-of-concept studies in cerebral small vessel disease.
If cognitive outcome measures are added to protocols, then sample size estimates increase substantially. Our data
support the use of an executive test battery rather than the Vascular Dementia Assessment Scale as the primary cognitive
outcome measure. (Stroke. 2012;43:2643-2647.)
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There is convincing evidence for progression of age-related white matter lesions (WML) from numerous
population-based, community-dwelling, and hospital-based
studies.1–11 Lesion progression occurs particularly in subjects
with confluent lesions at baseline and parallels cognitive
decline.2,5,9,12,13 WML progression was considered as a po-
tential surrogate marker in therapeutic trials of cerebral small
vessel disease; sample size calculations for trials using
change in WML volume as outcome measures are available.14
The use of magnetic resonance imaging (MRI) surrogate
markers such as WML progression may be helpful in proof-
of-concept studies, but it is also desirable to know if therapy-
related slowing of WML progression translates into signifi-
cant slowing of cognitive deterioration.
Volumetric measurements of WML change are still labor-
intensive and time-consuming, and most still need user
interference. Specifically designed visual rating scales facil-
itate assessment and their sensitivity and reliability have been
determined by comparing visual rating results with volumet-
ric data in identical subjects.1,15–17
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The Leukoaraiosis and Disability Study (LADIS) used the
visual Rotterdam Progression Scale (RPS) to determine the
change of white matter abnormalities over the course of 3
years and found lesion progression of various degrees in 74%
of study participants.18
We extend previous work by evaluating the association
between different grades of WML progression on the RPS
and on cognitive functioning and by providing sample size
calculations for clinical studies applying visually rated WML
progression as surrogate end points.
Subjects and Methods
Data were collected as part of the multicenter, multinational LADIS
study. The rationale and design of LADIS have been described
elsewhere.19,20 In short, 639 elderly subjects were enrolled in a
hospital-based setting. Included subjects had to be between age 65
and 84 years, had to show WML on MRI of any degree,21 had no or
only mild disability on the instrumental activities of daily living
scale,22 had a knowledgeable informant, and signed an informed
consent. Exclusion criteria were: likelihood of dropping out because
of the presence of severe illnesses (eg, cardiac, hepatic, renal failure),
cancer, or other relevant systemic diseases; severe unrelated neuro-
logical diseases; leukoencephalopathy of nonvascular origin (immu-
nologic, demyelinating, metabolic, toxic, infectious); severe psychi-
atric disorders; inability to provide informed consent; and inability or
refusal to undergo cerebral MRI. Subjects were selected and strati-
fied for WML severity according to the categorization of the
modified Fazekas scale into 3 severity classes.19 The cohort was
followed-up for 3 years. Reasons for dropouts during the observa-
tional period were death for 43, withdrawal of consent for 73, and
refusal to undergo follow-up examination or second MRI scan in 73
subjects. In 1 center (47 individuals), funding was lacking for
rescanning. Moreover, scans from 7 participants were excluded
because of absent fluid attenuation inversion recovery images or
inappropriate slice positioning, and in 2 subjects WML progression
could not be evaluated because of bilateral infarctions. The current
study cohort thus consists of those 394 study participants who
underwent a baseline and 3-year follow-up scan that could be
evaluated for WML progression. Their mean age was 73.15.0
years. There were 210 (53.3%) women and 184 (46.7%) men. As
described previously, subjects who underwent a follow-up MRI were
younger, had higher education, higher diastolic blood pressure, lower
total cholesterol, higher low-density lipoprotein, triglyceride, and
glucose levels than subjects who were not scanned at follow-up. We
also reported elsewhere that baseline MRI characteristics were
comparable between the groups with and without follow-up MRI.18
MRI Scanning and WML Progression Rating
MRI scanning at baseline was performed on 1.5-T scanners in 10
centers and on a 0.5-T machine in 1 center. Repeat scanning after 3
years was uniformly performed at a field strength of 1.5 T with 3
new MRI scanners (all 1.5 T) used. Thus, there was a change in field
strength of the scanner in only 1 center. The magnetic resonance
protocol has been described previously.18 It was kept identical over
the observational time in all centers.
At follow-up, visual rating of WML progression was performed in
a side-by-side fashion blinded to clinical data. WML progression
was rated on fluid attenuation inversion recovery images according
to the modified RPS,16 in which absence or presence of progression
(0 or 1, respectively) was rated in 3 periventricular regions (frontal
caps, occipital caps, bands), 4 subcortical white matter regions
(frontal, parietal, occipital, temporal), basal ganglia, and infratento-
rial region. The total progression score ranges from 0 to 9. The
intrarater reliability was determined on 20 randomly selected scans
that were scored twice, and calculation of weighted Cohen kappa
resulted in an excellent 0.81 agreement.
Neuropsychological Testing
The test battery applied to all LADIS participants has been described
elsewhere.20 For the purpose of this study, we used the Vascular
Dementia Assessment Scale (VADAS-cog)23 and a composite score of
executive function testing. The VADAS-cog scale comprises the Alz-
heimer Disease Assessment Scale24 and 6 subtests covering the cogni-
tive domains attention, working memory, executive functions, and
mental speed, which are frequently involved in vascular cognitive
impairment.25 The VADAS-cog was applied according to the original
version24 except for using only 1 trial instead of the original 3 when
assessing word recall and word recognition to avoid an overly long test
administration. The scoring system was identical to that used in the
original version. The 5 tests added to the Alzheimer Disease Assessment
Scale are a delayed recall of a word list, digit cancellation, a maze task,
the symbol-digit-modalities test, digit span backward test, and verbal
fluency test (animal category). The scoring methods used for these tests
have been previously described.26 The VADAS-cog total score ranges
from 0 (no impairment) to 120 (maximal impairment). Four tests
specifically measured executive functions. These included the Stroop
color-word test, the trail-making test, the symbol-digit-modalities test,
and a verbal fluency test. To calculate an executive function score, all
test results were z-transformed. For Stroop color-word test and the
trail-making test, we focused on working speed and thus calculated the
differences between time color-word card minus time color card, and
time trail-making test version B minus time trail-making test version A,
respectively. These difference scores were inverted (higher score de-
notes better performance) and added to the symbol-digit-modalities test
and verbal fluency test scores, and a mean z-score was then calculated.
Statistical Analysis
The RPS was evaluated for the whole sample and the 3 WML
groups. Differences in progression between the 3 WML groups were
analyzed by a 2 test. The Jonckheere Terpstra test was used to
investigate the association between the change on RPS and change
on VADAS-cog and the executive function score (EFS) over the
course of the 3-year follow-up period. Based on these results, we
performed sample size calculations for various scenarios of future
clinical trials. All sample size calculations assumed a power of 80%
and a 2-sided significance level of 5%. Calculations were based on
the assumption that a particular treatment could reduce WML
progression on the RPS by 1 grade over the course of the 3-year
follow-up period. The sample size needed to detect reduced WML
progression as the sole outcome was calculated by the Wilcoxon test.
To determine the effect of reduced WML progression by 1 RPS
grade on VADAS-cog and on EFS, we calculated a weighted mean.
The mean of these scores in each RPS grade was weighted with the
percentage of cases that would be expected within each grade after
treatment. The sample sizes for the differences of the changes on
VADAS-cog and EFS were then determined using a t test. All
analyses were performed using PASW18 Statistics, and P0.05 was
considered significant. For sample size calculation, nQuery Advisor
7.0 was used.
Results
The frequency of WML progression on the RPS is shown in
Table 1. Results are given for the total sample and subsets
with different WML grades at baseline. Any progression was
seen in 290 (73.6%) of the 394 study participants. One
hundred two (57.3%) participants with punctate WML, 110
(89.4%) with early confluent WML, and 78 (83.9%) with
confluent WML at baseline showed WML progression after 3
years (P0.0001). Baseline WML grade influenced the
magnitude of future WML progression. A change of 4
grades on the RPS was present in only 12 (6.7%) individuals
with punctate WML, whereas this was seen in 32 (26.0%)
subjects with early confluent and 29 (31.2%) with confluent
abnormalities (P0.0001).
2644 Stroke October 2012
There were 346 (87.8%) individuals who underwent both
baseline and 3-year testing on VADAS-cog. A total of 313
participants repeated executive function testing. Over the
course of the observational period, study participants deteri-
orated by 2.68.5 points (range, 23 to 39 points) on
VADAS-cog and 0.70.44 points on the EFS. As can be
seen from the Figure, the magnitude of decline on VADAS-
cog increased in an almost linear fashion with increasing
progression of WML. Similar associations existed for the
EFS.
Change on VADAS-cog and on EFS in the whole study
sample and in the subset of subjects with grade 2 and 3 WML
at baseline is given in Table 2. We found a significant inverse
association between WML progression rating and cognitive
functioning on VADAS-cog in the total cohort, whereas no
such relationship was observed in the subset of individuals
with early confluent or confluent WML at baseline. WML
progression also related to deterioration in EFS. Again, this
association was only significant for the entire study cohort
but not for individuals with grade 2 or 3 white matter
changes.
Based on these data, we performed sample size calculations
for clinical trials assessing 3 different scenarios. In the first
scenario, the outcome measure is considered to be the reduction
of WML progression on the RPS by 1 grade without attention
being given on the resulting cognitive change. The second and
third scenarios consider the change on VADAS-cog and on
EFS resulting from the reduction of WML progression as the
outcome measures. As can be seen from Table 3, low
numbers of subjects are required per treatment arm in
scenario 1 trials in which WML progression is the primary
outcome measure. Such settings allow for a further lowered
sample size when including individuals with grade 2 or 3
WML, only. For scenarios 2 and 3, in which the expected
change in cognition resulting from treatment effects on WML
progression is used as the outcome, 2599 or 18 853 subjects
per treatment arm would be required for VADAS-cog and
1809 or 1988 for EFS. Sample size strongly depends on both
baseline WML grade and applied cognitive tests. Trials that
would include only subjects with grade 2 or 3 WML at
baseline and that use the VADAS-cog as cognitive outcome
would require a sample size of 18 53 subjects per treatment
arm.
Discussion
We found that using WML progression as an outcome
measure in intervention trials in cerebral small vessel disease
would require considerably less subjects compared with trials
including cognitive outcome measures. Our study used the
RPS to rate WML change over a 3-year observational period.
As compared with quantitative methods, this scale allows for
visual, and thus less labor-intensive and time-consuming,
assessment of WML progression with good correlation to
volumetric measurements.17 Other than volumetric measure-
ment of WML progression visual rating is less likely to be
affected by technical upgrades of MRI machines and changes
in scanning sequences over time. During the conduct of the
current study, MRI scanners were renewed in 3 study centers,
with 1 center switching to a magnet with higher field strength.
Thus, the results of the present study cannot be extrapolated
to more sophisticated techniques of measuring change in
WML which, however, may suffer from other difficulties
when applied in a multicenter setting.
In line with previous studies, we showed baseline WML
grade to be the strongest predictor of future progression.27
Consequently, interventional studies aiming to slow WML
progression might enrich their study populations for partici-
pants with early confluent and confluent abnormalities to
reduce sample size. According to previous reports of the
Austrian Stroke Prevention Study14 and current LADIS data,
3-year intervention trials applying modestly effective treat-
ments in subjects with grade 2 or 3 WML at baseline will
need relatively small samples ranging between 116 and 490
subjects14 to provide significant results.
Table 1. Extent of White Matter Lesion Progression at 3-Year
Follow-Up on Visual Rating According to Baseline White Matter
Lesion Grade
Rotterdam
Progression
Scale Rating
Punctate
(n178)
Early
Confluent
(n123)
Confluent
(n93)
Total*
(n394)
0 76 (42.7%) 13 (10.6%) 15 (16.1%) 104 (26.4%)
1 48 (27.0%) 19 (15.4%) 17 (18.3%) 84 (21.3%)
2 26 (14.6%) 33 (26.8%) 18 (19.4%) 77 (19.5%)
3 16 (9.0%) 26 (21.1%) 14 (15.1%) 56 (14.2%)
4 6 (3.4%) 14 (11.4%) 11 (11.8%) 31 (7.9%)
5 4 (2.2%) 9 (7.3%) 9 (9.7%) 22 (5.6%)
6 2 (1.1%) 8 (6.5%) 7 (7.5%) 17 (4.3%)
7 1 (0.8%) 1 (1.1%) 2 (0.5%)
8 1 (1.1%) 1 (0.3%)
RPS indicates Rotterdam Progression Scale.
*RPS rating for the total group was first reported in reference 18.
Figure. Associations between categories of 3-year white matter
lesion (WML) progression and change on Vascular Dementia
Assessment Scale (VADAS-cog). At each category of visual
WML progression rating, the median of VADAS-cog change is
displayed by the central mark within the box. Box edges repre-
sent the 25th and 75th percentile values. Whiskers extend to the
most extreme data points not considering outliers. Increasing
WML progression was significantly related to deterioration on
the VADAS-cog (Jonckheere Terpstra test; P0.004).
Schmidt et al White Matter Lesion Progression in LADIS 2645
The situation changes dramatically if clinical effects re-
lated to WML progression are used as study outcome. As
expected, there was a significant but only moderate relation-
ship between lesion progression and decline in cognitive
performance. Much to our surprise, this association became
attenuated rather than enhanced when focusing on subjects
with grade 2 or 3 lesions. This was caused by a pronounced
cognitive deterioration in individuals with early confluent or
confluent lesions at baseline, irrespective of change in lesion
extent. Individuals with early confluent and confluent abnor-
malities at the initial examination but no lesion progression
over the next 3 years experienced an even greater deteriora-
tion on VADAS-cog than those with the same lesion extent at
baseline and mild to moderate WML progression during
follow-up. Only those individuals with grade 2 or 3 lesions
who later experienced 5 grades of progression had a
cognitive decline beyond the value observed in subjects with
no WML progression at all. Similar relationships also were
observed for performance on executive function tests. These
complex associations between longitudinal WML and cogni-
tive change severely affect sample size estimates for trials
using cognitive change resulting from treatment-related slow-
ing of lesion progression as the primary outcome measure.
Given that any treatment slows WML progression by 1 grade
over a 3-year time period, such trials will need to be
excessively larger than studies with WML change as the sole
outcome. When including individuals with any WML grade,
2599 subjects would have to be recruited per treatment arm to
detect a significant difference on VADAS-cog and 1809
subjects would have to be recruited for the composite EFS.
For executive function, this estimate could be reduced if
subjects with only grade 2 and 3 lesions were included, but
with 18 853 participants per group the numbers would be-
come extremely high for VADAS-cog. The LADIS sample
likely reflects the patient population with WML encountered
in everyday clinical practice, although it was stratified for
lesion severity19 and did not include subjects with dementia.
Thus, one cannot exclude that sample size calculations may
not be fully applicable to trials focusing on dementia cases.
Current sample size estimates are based on the simplifying
assumption that a given treatment could decrease lesion
progression by 1 grade consistently over all categories of
WML progression. Such a scenario would be unusual, and
thus we can only provide approximate sample size estimates.
Despite these uncertainties, such calculations are important
because they show that the dimensions of clinical trials using
WML progression ratings as surrogate outcomes need to
change tremendously once investigators strive to demonstrate
beneficial effects not only on WML progression but also on
cognitive functioning.
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Table 2. Association Between 3-Year White Matter Lesion Progression Rating and Subsequent Change in Performance on Vascular
Dementia Assessment Scale or Executive Function Score
Rotterdam
Progression
Scale Rating
All WML Grades WML Grade 2 and 3
Change in VADAS-Cog
Change in Executive
Function Score Change in VADAS-Cog
Change in Executive
Function Score
N Mean (SD) P* Value N Mean (SD) P* Value N Mean (SD) P* Value N Mean (SD) P* Value
0 94 1.02 (7.35) 90 0.02 (0.34) 25 4.10 (7.10) 23 0.14 (0.36)
1 73 1.66 (7.35) 70 0.08 (0.40) 33 2.21 (7.90) 31 0.17 (0.42)
2 72 2.65 (10.10) 62 0.05 (0.47) 46 2.59 (11.27) 39 0.06 (0.48)
3 48 3.98 (7.68) 42 0.14 (0.51) 34 3.53 (7.68) 28 0.16 (0.46)
4 25 3.20 (10.31) 21 0.15 (0.48) 20 3.70 (10.10) 15 0.10 (0.46)
5 18 7.00 (8.45) 14 0.33 (0.50) 16 6.00 (7.78) 13 0.37 (0.51)
6 13 6.54 (10.10) 11 0.29 (0.51) 11 7.73 (10.10) 9 0.36 (0.51)
7 3 6.00 (4.36) 0.004 3 0.16 (0.37) 0.002 3 6.00 (4.36) 0.24 3 0.16 (0.37) 0.12
SD indicates standard deviation; VADAS-cog, Vascular Dementia Assessment Scale; WML, white matter lesion.
*Jonckheere Terpstra rest.
Table 3. Sample Sizes per Treatment Arm According to
Lesion Grade at Baseline in a 3-Year Trial in Which Treatment
Reduces White Matter Lesion Progression by One Grade*
Trial Outcome Measures
All WML
Grades
Early Confluent and
Confluent WML
Reduction of WML progression 70 58
VADAS-cog Change resulting from
reduction of WML progression
2599 18 853
Executive function change resulting
from reduction of WML progression
1809 1988
VADAS-cog indicates Vascular Dementia Assessment Scale; WML, white
matter lesion.
*All calculations assumed a power of 0.80 and a two-sided significance level
of 5%.
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